BioSpace News Archive

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced it will release its third quarter 2022 financial and operating results on Tuesday, November 8, 2022, following the close of trading.

AcelRx Pharmaceuticals, Inc. today announced that an abstract entitled, “Evolution Of Opioid Analgesia On The Battlefield For Moderate-to-Severe Acute Pain” (abstract # A4123) was presented by lead author, Sharon Kim, M.S., at the ANESTHESIOLOGY® 2022 annual meeting, held October 21-25, 2022 in New Orleans, LA.

Ginkgo Bioworks and the Ministry of Investment of Saudi Arabia today announced that they have entered into a non-binding Memorandum of Understanding with the intent of developing biotechnology and biosecurity capabilities to deploy new public health initiatives in the Kingdom of Saudi Arabia.

Evolus, Inc. today announced that it will report its third quarter 2022 financial results and provide a business update on Tuesday, November 8, 2022, after the U.S. financial markets close.

Biora Therapeutics, Inc today presented detailed results from its PM-602 study titled “A scintigraphic study to evaluate the localization and delivery function of a Drug Delivery System (DDS) device in patients with active ulcerative colitis (UC) in fasted state” during the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting.

ObvioHealth, a global Virtual Research Organization (VRO) pioneering end-to-end decentralized clinical trials (DCT), is collaborating with Oracle in Asia Pacific to help get breakthrough therapies to market faster through more efficient integration of diverse data sets.

Anika Therapeutics, Inc. today announced that the Company plans to issue its third quarter 2022 financial results after the close of the market on Tuesday, November 8, 2022 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights.

Mentice AB (publ), Gothenburg, a world leader in simulation solutions for image-guided interventional therapies, announced today that Acandis, Pforzheim, a leading innovator of minimal invasive devices for the treatment of neurovascular diseases, has signed a 3-year collaboration agreement to further develop the Acandis clinical support platform and supply their customers with Mentice Ankyras clinical support software solutions.

Hugel Aesthetics Receives FDA Acceptance of BLA Resubmission for LetibotulinumtoxinA for Injection for Glabellar Lines.

Cour Pharmaceuticals a clinical-stage biotechnology company developing novel immune-modifying nanoparticles designed to reprogram the immune system for the treatment of autoimmune disorders (COUR NanoParticles or CNPs), today announced that the U.S. Food and Drug Administration has cleared an Investigational New Drug (IND) application to initiate a Phase 1b/2a proof-of-concept study of COUR’s investigational therapy, CNP-106.